Publication date: Jun 03, 2025
This study aimed to identify risk and prognostic factors of Pneumocystis jirovecii pneumonia (PJP) in patients with anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis (anti-MDA5+DM). We conducted a retrospective cohort study of anti-MDA5+DM patients who underwent metagenomic next-generation sequencing analysis of bronchoalveolar lavage fluid or lung tissue at our center between January 2019 and February 2023. Eligible patients were stratified into PJP+ and PJP- groups based on PJP status. Potential risk factors and prognostic indicators for PJP were analysed using univariate and multivariate logistic regression analysis. A total of 107 anti-MDA5+DM patients were enrolled, of whom 47 were assigned to the PJP+ group. Multivariate logistic regression analysis revealed older age and high cumulative dosage of glucocorticoids within 3 months preceding PJP diagnosis were independent risk factors for PJP development. Conversely, prophylactic-dose trimethoprim-sulfamethoxazole (TMP/SMZ) was associated with a significantly reduced risk of PJP (all p
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | Pneumocystis jirovecii pneumonia |
| disease | MESH | dermatomyositis |
| disease | MESH | melanoma |
| pathway | KEGG | Melanoma |
| drug | DRUGBANK | Dextromethorphan |
| drug | DRUGBANK | Thymidine monophosphate |
| drug | DRUGBANK | Sulfamethazine |